Everolimus Related Pneumonitis in MBC

Drug-related Pneumonitis During mTOR Inhibitor Therapy in Patients With Metastatic Breast Cancer: A Radiographic Patternbased Approach

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03730428

Enrollment

Registered

2018-11-05

Start date

2017-07-15

Completion date

2020-06-15

Last updated

2020-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Everolimus, Pneumonitis

Brief summary

To study the drug-related pneumonitis during mTOR inhibitor therapy in patients with metastatic breast cancer.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Postmenopausal woman (or premenopausal women treated with LHRHa) diagnosed with HR+，HER2- metastatic breast cancer 2. Treated with everolimus for at least one month in metastatic setting 3. With baseline and at least one follow-up chest CT during everolimus therapy. 4. Complete medical history

Exclusion criteria

1. Incomplete medical history 2. Radiographic imaging unavailable

Design outcomes

Primary

Measure	Time frame	Description
radiographic pattern	2 months	Quantitive measure of lung CT
PFS	2 months	Progression free survival

Countries

China

Outcome results